Conceptual approaches to metastatic disease

Annals of Oncology

Volumn 23, Issue SUPPL. 10, 2012, Pages

  Seymour, M ^a  

^a UNIVERSITY OF LEEDS   (United Kingdom)

Author keywords

Colorectal cancer; Intermittent chemotherapy; Palliative chemotherapy; Stop and go strategy

Indexed keywords

BEVACIZUMAB; CAPECITABINE; CETUXIMAB; FLUOROPYRIMIDINE; FLUOROURACIL; OXALIPLATIN;

ABLATION THERAPY; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER PROGNOSIS; CANCER SURGERY; CANCER SURVIVAL; CLINICAL EVALUATION; COLORECTAL CANCER; DRUG INTERMITTENT THERAPY; HUMAN; LONG TERM SURVIVAL; MAINTENANCE THERAPY; METASTASIS; MULTIMODALITY CANCER THERAPY; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PALLIATIVE THERAPY; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; QUALITY OF LIFE; SURVIVAL TIME;

CLINICAL TRIALS AS TOPIC; COLORECTAL NEOPLASMS; DECISION MAKING; HUMANS; NEOPLASM METASTASIS; TREATMENT OUTCOME;

EID: 84866767041     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mds361     Document Type: Article

References (11)

1. Seymour MT, Punt CJA. Sequential chemotherapy for advanced colorectal cancer: should we ever start with a single cytotoxic agent? Curr Colorect Cancer Rep 2008; 4: 130-138.
2. Ducreux M, Malka D, Mendiboure J et al. Sequential versus combination chemotherapy for the treatment of advanced colorectal cancer (FFCD 2000-05): an open-label, randomised, phase 3 trial. Lancet Oncol 2011; 12: 1032-1044.
3. Seymour MT, Maughan TS, Ledermann JA et al. Different strategies of sequential and combination chemotherapy for patients with poor- prognosis advanced colorectal cancer (MRC FOCUS): a randomised controlled trial. Lancet 2007; 370: 143-152.
4. Buyse M, Burzykowski T, Carroll K et al. Progression-free survival is a surrogate for survival in advanced colorectal cancer. J Clin Oncol 2007; 25: 5218-5224.
5. Chibaudel B, Bonnetain F, Shi Q et al. Alternative end points to evaluate a therapeutic strategy in advanced colorectal cancer: evaluation of progression-free survival, duration of disease control, and time to failure of strategy-an Aide et Recherche en Cancerologie Digestive Group Study. J Clin Oncol 2011; 29: 4199-4204.
6. Adams RA, Meade AM, Seymour MT et al. Intermittent versus continuous oxaliplatin and fluoropyrimidine combination chemotherapy for first-line treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial. Lancet Oncol 2011; 12: 642-653.
7. de Gramont A, Buyse M, Abrahantes JC et al. Reintroduction of oxaliplatin is associated with improved survival in advanced colorectal cancer. J Clin Oncol 2007; 25: 3224-3229.
8. Chibaudel B, Maindrault-Goebel F, Lledo G et al. Can chemotherapy be discontinued in unresectable metastatic colorectal cancer? The GERCOR OPTIMOX2 Study. J Clin Oncol 2009; 27: 5727.
9. Tveit KM, Guren T, Glimelius B et al. Phase III trial of cetuximab with continuous or intermittent fluorouracil, leucovorin, and oxaliplatin (Nordic FLOX) versus FLOX alone in first-line treatment of metastatic colorectal cancer: the NORDIC-VII study. J Clin Oncol 2012; 30: 1755-1762.
10. Tabernero J, Aranda E, Gomez A et al. Phase III study of first-line XELOX plus bevacizumab for 6 cycles followed by XELOX plus BEV or single-agent (s/a) BEV as maintenance therapy in patients with metastatic colorectal cancer: The MACRO Trial. J Clin Oncol 2010; 28(Suppl.): 15s (Abstr. 3501).
11. Wasan H, Adams RA, Wilson RH et al. Intermittent chemotherapy (CT) plus continuous or intermittent cetuximab (C) in the first-line treatment of advanced colorectal cancer (aCRC): results of the two-arm phase II randomized MRC COINb trial. J Clin Oncol 2012; 30(Suppl 4) (Abstr. 536).